English, Article edition: From Randomised Clinical Trials to Clinical Practice: A Pragmatic Cost-Effectiveness Analysis of Paclitaxel in First-Line Therapy for Advanced Ovarian Cancer Samuel Limat; Marie-Christine Woronoff-Lemsi; Celine Menat; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/119788
Physical Description
  • article
Language
  • English

Edition details

Title
  • From Randomised Clinical Trials to Clinical Practice: A Pragmatic Cost-Effectiveness Analysis of Paclitaxel in First-Line Therapy for Advanced Ovarian Cancer
Author
  • Samuel Limat
  • Marie-Christine Woronoff-Lemsi
  • Celine Menat
  • Anne Madroszyk-Flandin
  • Yacine Merrouche
Physical Description
  • article
Notes
  • Introduction: Paclitaxel plus cisplatin is considered to be the standard first-line therapy for advanced ovarian cancer. Previous to this study, economic data on this combination resulted from randomised clinical trials (RCTs). Therefore, the objective of this study was to compare the clinical and economic outcomes associated with paclitaxel-cisplatin (PC) and cyclophosphamide-cisplatin (CC) regimens using a pragmatic perspective based on daily clinical practice in a French university hospital. Method: A retrospective cost-effectiveness analysis, from the hospital-payer perspective, was carried out as a before-after case study in fifty-nine consecutive women with verified International Federation of Gynaecology and Obstetrics (FIGO) stage II, III or IV ovarian cancer treated between 1995 and 2000. Median overall survival (OS) was used as the primary endpoint. The quality-adjusted time was assessed by the quality-adjusted time without symptoms or toxicity (Q-TWiST) method. Direct medical costs were collected for each patient. Monetary values for French prices in the year 2000 were used and converted to US dollars using an exchange rate of $US1 =​ 7 French francs. Several univariate sensitivity analyses were carried out varying unit costs, medical practices and administration of paclitaxel. Results: The incremental cost of the PC regimen was $US10 Conclusion: Our study suggests that PC may be a cost-effective regimen for advanced ovarian cancer in a French university hospital setting. We reported higher incremental costs and lower clinical benefits than RCT-based findings, suggesting that RCT-based findings were clearly balanced by our pragmatic approach based on clinical practices. Observational studies can provide complementary and balanced data for decision making.
  • Alkylating-agents, Cisplatin, Cost-effectiveness, Cost-utility, Cyclophosphamide, Ovarian-cancer, Paclitaxel, Taxanes, Platinum-complexes
  • RePEc:wkh:phecon:v:22:y:2004:i:10:p:633-641
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment